OncoMatch

OncoMatch/Clinical Trials/NCT05536141

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Is NCT05536141 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including casdatifan and Cabozantinib for clear cell renal cell carcinoma.

Phase 1RecruitingArcus Biosciences, Inc.NCT05536141Data as of May 2026

Treatment: casdatifan · Cabozantinib · Zimberelimab · Ipilimumab — The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: hypoxia inducible factor (HIF)-2α inhibitor

prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor

Cannot have received: (cabozantinib)

For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib

Cannot have received: systemic treatment

For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present

Lab requirements

Kidney function

creatinine clearance ≥ 40 ml/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Alabama at Birmingham · Birmingham, Alabama
  • University of California at San Diego · San Diego, California
  • UCLA · Santa Monica, California
  • University of Miami · Miami, Florida
  • Emory University · Atlanta, Georgia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify